BioPharm International interviews Tarja Mottram, CEO of Action for Results, about a paradigm shift in how we measure and provide evidence for the impact of a product on healthcare outcomes. Posted Feb. 2012.
In part II of this BioPharm International interview, Tarja Mottram, CEO of Action for Results, focuses on “design for value”—a paradigm shift in how the industry measures and provides evidence for the impact of a product on healthcare outcomes. Posted Feb. 2012
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.